Hair Follicle Targeting Via Gelatin Coated Transferosomes Loaded With Tofacitinib Citrate For Enhanced Treatment Of Alopecia Areata: Clinical Evaluation Of Alopecia Areata Patients

January 2025 in “ International Journal of Pharmaceutics ”

Hamss Gabr, Mohammad Abdel‐Halim, Basma Mourad, Mai Rady, Samar Mansour

gelatin-coated transferosomes tofacitinib citrate alopecia areata hair follicles GLTS gel GLTS

Studysummary In this study, gelatin-coated transferosomes were developed to deliver tofacitinib specifically to hair follicles, resulting in 80% hair regrowth in alopecia areata patients with recalcitrant lesions after 12 weeks of treatment.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on sciencedirect.com →

Discuss this study in the Community →

Research cited in this study

21 / 21 results

research Nanostructured Lipid Carriers Promote Percutaneous Absorption and Hair Follicle Targeting of Tofacitinib for Treating Alopecia Areata

July 2024 in “Journal of Controlled Release”

In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.

research Safety and Efficacy of Tofacitinib in 97 Alopecia Areata Patients

May 2024 in “Journal of cosmetic dermatology”

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

research Drug Survival and Long-Term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study

2 citations , November 2023 in “Acta dermato-venereologica”

This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.

research Two Phase III Trials of Baricitinib for Alopecia Areata: A Critically Appraised Research Paper

5 citations , October 2022 in “British Journal of Dermatology”

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

research Transferosomes Versus Transethosomes for the Dermal Delivery of Minoxidil: Preparation and In Vitro/Ex Vivo Appraisal

3 citations , September 2022 in “Journal of Drug Delivery Science and Technology”

This study reported that encapsulating minoxidil in transferosomes and transethosomes can enhance skin permeability and drug retention compared to its conventional formulation, potentially increasing efficacy in androgenic alopecia treatment while reducing side effects, especially when transethosomes contain oleic acid.

research Glycyrrhizin Micellar Nanocarriers for Topical Delivery of Baicalin to the Hair Follicles: A Targeted Approach Tailored for Alopecia Treatment

24 citations , August 2022 in “International Journal of Pharmaceutics”

Glycyrrhizin nanocarriers effectively deliver baicalin to hair follicles, promoting hair growth and offering a promising alopecia treatment with fewer side effects.

Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study

research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study

8 citations , June 2022 in “Frontiers in Medicine”

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

research Evaluation of the Level of Serum Interleukins (IL-2, IL-4, IL-15, and IL-17) and Its Relationship with Disease Severity in Patients with Alopecia Areata

14 citations , July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia”

This study found that alopecia areata patients had higher baseline interleukin levels, which significantly decreased with tofacitinib treatment, though this change did not correspond to disease severity improvement.

research Enhancing Permeation of Drug Molecules Across the Skin via Delivery in Nanocarriers: Novel Strategies for Effective Transdermal Applications

365 citations , March 2021 in “Frontiers in Bioengineering and Biotechnology”

This review discusses the potential of nanocarriers to enhance transdermal drug delivery and the combination of these carriers with physical methods, but it reports no new experimental results.

research Efficacy and Safety of Combination of Mometasone Furoate 0.1% Cream and Adapalene 0.1% Gel in Alopecia Areata

February 2020 in “Zagazig University Medical Journal”

In this study, 40 alopecia areata patients applied a combination of adapalene gel and mometasone furoate cream for 6 months, leading to 35% achieving full hair regrowth, though 85% experienced mild side effects like irritation.

research Oleic Acid Nanovesicles of Minoxidil for Enhanced Follicular Delivery

27 citations , September 2018 in “Medicines”

This study reported that oleic acid-based nanovesicles improve follicular delivery and reduce side effects of minoxidil compared to traditional MXD lotions.

research JAK Inhibitors: New Players in the Field of Immune-Mediated Diseases Beyond Rheumatoid Arthritis

223 citations , September 2018 in “Rheumatology”

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

research Alopecia Areata: A Clinician's Guide

1 citations , January 2018 in “Springer eBooks”

The book helps doctors understand and treat alopecia areata.

research Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management

102 citations , December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”

This review discusses the role of immune privilege collapse in the pathogenesis of alopecia areata, emphasizing the potential for therapeutic manipulation of hair bulb immune privilege to offer new treatment options, and reports no new results.

research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients

48 citations , November 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

research Treatment of Alopecia Areata With Tofacitinib

78 citations , March 2017 in “JAMA Dermatology”

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

research Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo

March 2017 in “Current dermatology reports”

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations , January 2017 in “Journal of the American Academy of Dermatology”

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

research Applications and Limitations of Lipid Nanoparticles in Dermal and Transdermal Drug Delivery via the Follicular Route

95 citations , July 2015 in “European journal of pharmaceutics and biopharmaceutics”

This review discusses the application of lipid nanoparticles for enhancing drug delivery through hair follicles and reports no new clinical results, emphasizing the potential role of sebum-like lipids in this context.

research Delivery and Targeting of Nanoparticles into Hair Follicles

94 citations , September 2014 in “Therapeutic Delivery”

This review describes recent advances in using nanoparticles for drug delivery to hair follicles, with potential applications in treating skin diseases such as alopecia and acne, but reports no new findings.